|Day Low/High||116.92 / 118.90|
|52 Wk Low/High||73.69 / 119.84|
Big pharma is shaping up to be a consolidating category in 2019.
REACH-2 is the first positive Phase 3 hepatocellular carcinoma trial in a biomarker-selected population known for poor prognosis
Eli Lilly falls as a Phase 3 trial of drug for treatment of sarcoma didn't meet its primary endpoint.
Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Lilly (Eli) & Co , where a total volume of 44,518 contracts has been traded thus far today, a contract volume which is representative of approximately 4.5 million underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 86.7% of LLY's average daily trading volume over the past month, of 5.1 million shares.
- Study did not meet the primary endpoints of overall survival (OS) in the full study population or in the leiomyosarcoma (LMS) sub-population; there was no difference in survival between the study arms for either population.
So far 2019 is proving to be a year where things have a habit of working out right.
Jim Cramer looks at the run in the financial stocks and says banks are leading this market back.
Left's firm Citron Research gives the $100+ stock a $35 price target.
Deals that simply were unworkable four months ago because of price are now being done with alacrity.
One of pharma's biggest CEO's talks M&A action on the exchange.
Do we have to run for the hills? Not necessarily.
Newmont Mining will acquire Goldcorp in a $10 billion deal, and here's how I'd trade Newmont.
My stated reason for being in Pfizer all along has been price stability and income.
This is the kind of reversal that happens in a bull market.
NEW YORK, Jan. 8, 2019 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the Board of Directors of Loxo Oncology, Inc.
Could there be more M&A this year than Wall Street had thought? Also, GE's quest for more liquidity took another baby step Monday.
Jim Cramer says companies that innovate become market-leading stocks, and can create tremendous wealth.
NEW YORK, Jan. 7, 2019 /PRNewswire/ -- Rowley Law PLLC is investigating potential claims against Loxo Oncology, Inc.
Tesla, the big pharma mergers and General Electric are some of the top stories on TheStreet.
Luxoft is to be bought for about $2 billion by DXC Technology.
We're out in San Francisco this week covering the amazing innovations that so many companies reveal at this annual conference.
The Dow Jones Industrial Average is higher Monday amid improved prospects for a trade deal between the U.S. and China.
The company expects revenue to jump 12% year over year.
Eli Lilly & Co. says Monday it will pay $8 billion in cash for cancer drug specialists Loxo Oncology in the second major pharmaceutical sector deal of the year.
Bigfoot Biomedical, Inc., a diabetes company using artificial intelligence to develop solutions for optimizing the dosing and delivery of insulin, today announced a non-exclusive cooperation agreement with Eli Lilly and Company (NYSE: LLY) to support...
Global stocks traded higher Monday, following on from Friday's spectacular rally on Wall Street, as investors cheered much stronger-than-expected U.S. jobs data paired with twin dovish messages from the Federal Reserve and the People's Bank of China that look to support beaten-down asset prices heading into the fourth quarter earnings season.
Pharma companies that have cash are looking at what has happened to this stock market and buying.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.